Abstract 2097P
Background
OM is one of the main adverse events during chemotherapy, affecting around 40% of pts; it is characterized by an inflammation and ulceration of the oral mucous membranes that can lead to oral pain, impaired nutritional intake, local or systemic infections and lower quality of life. Only few strategies are available for its prevention and management. FP-based tp can cause OM due to their cytotoxic effect on mucosal cells inducing DNA double strand brakes and ROS production, empowered by TNF-alfa release. In our retrospective monocentric study we evaluated clinical and hematological RFs which could help us to identify early those patients who might benefit the most from a preventive strategy.
Methods
We evaluated incidence, management and possible RFs for OM (such as diabetes, smoke, BMI and blood inflammation markers) on 174 pts treated with a FP-based tp during a typical month in our DH. Statistical analysis has been conducted using Chi-square test and Fisher’s exact test. Pts have been informed about risk of developing OM and we subsequently managed the symptom on the basis of its severity according to CTCAE.
Results
48 pts developed OM. We found a higher OM incidence in smoker pts (60.5% vs 21.4% in non smoker, p<0.0001) and in overweight pts (39.7% vs 24.1% in pts with normal weight, p=0.0381). We also demonstrated a correlation between a higher OM severity and diabetes diagnosis (71% vs 29.8% in non diabetic pts, p=0.0330). No statistically significant correlation emerged between OM incidence/severity and any of the blood values tested (blood cells values, NLR, PLR, creatinine). 20 pts had ≥G2 OM and received local and/or systemic therapies, while 3 pts needed a treatment suspension. Median time to resolution was 28 days. 6 pts still had OM of various severity grade at the time of our analysis.
Conclusions
Smoke and overweight could be RFs for OM incidence of any grade during a FP-based treatment, while a diabetes diagnosis seemed to be related with a higher severity of OM, but not with its incidence. In view of the above, it might be useful to recommend accurate oral hygiene and a preventive strategy in accordance with MASCC guidelines in these subgroups of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06